The Edge Consulting Group CEO Jim Osman tells Proactive Investors the investment research company that focuses on company spin-offs has compiled a report suggesting Merck & Co (NYSE: MRK) spin-off its animal health business, as the animal health business generates around $40 billion in revenue, The Edge expecting this to rise to $65 billion in 2025.
Osman says there’s significant value to be held to create even more value for its investors if the pharma giant does indeed spin off this portion of the business.